The pooled proportion of abnormal LFT parameters in COVID-19 positive patients showed significantly lower serum levels of albumin (estimate, 37.29; 95% CI, 33.85 to 40.72; I2=97.99%; pheterogeneity<0.0001), and significantly higher serum levels of AST (estimate, 33.84; 95% CI, 29.47 to 38.20; I2=96.03%; pheterogeneity<0.0001) and ALT (estimate, 27.93; 95% CI, 24.57 to 31.30; I2=91.35%; pheterogeneity<0.0001). The gene discussed is GPT; the disease is COVID-19.